about
Use of ibuprofen and risk of Parkinson diseaseDiethylstilbestrol exposure in utero and depression in womenDiabetes and risk of Parkinson's disease: a systematic review and meta-analysisBiochemical premotor biomarkers for Parkinson's diseaseReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsIdentification of key uric acid synthesis pathway in a unique mutant silkworm Bombyx mori model of Parkinson's diseaseMeeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007Gene-environment interactions: key to unraveling the mystery of Parkinson's diseaseTherapeutic directions for Parkinson's diseasePlasma apolipoprotein A1 as a biomarker for Parkinson diseaseThe role of biomarkers and imaging in Parkinson's disease.Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiologyUric acid and dementia in community-dwelling older persons.Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studiesBlood-based biomarkers for Parkinson's diseaseUric acid as a CNS antioxidantProtection by inosine in a cellular model of Parkinson's diseaseUrate as a predictor of the rate of clinical decline in Parkinson disease.Using 'omics' to define pathogenesis and biomarkers of Parkinson's disease.Physical activities and future risk of Parkinson disease.Reassessing serum urate targets in the management of refractory gout: can you go too low?Comorbidities in patients with crystal diseases and hyperuricemia.Plasma urate and Parkinson's disease in women.2011 recommendations for the diagnosis and management of gout and hyperuricemia.Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease.Nicotine as a potential neuroprotective agent for Parkinson's disease.Particulate matter and risk of Parkinson disease in a large prospective study of women.Mitochondrial dysfunction in Parkinson's disease: pathogenesis and neuroprotection.Mendelian randomization of serum urate and parkinson disease progression.Unbiased approaches to biomarker discovery in neurodegenerative diseasesUrate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis.Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.Alcohol Consumption, Types of Alcohol, and Parkinson's Disease.Gene-environment interactions in Parkinson's disease: the importance of animal modeling.Pathophysiological roles for purines: adenosine, caffeine and urate.The risk of Parkinson disease associated with urate in a community-based cohort of older adults.Serum urate and probability of dopaminergic deficit in early "Parkinson's disease".The effects of uric Acid, serum vitamin d3, and their interaction on Parkinson's disease severityClinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies.Uric acid levels predict survival in men with amyotrophic lateral sclerosis.
P2860
Q24594751-63C9C49D-9A68-4D2A-96CC-DD7E05075F26Q24605060-5D13377A-8A93-4414-AF2B-EF252513A61DQ26849796-2703076A-74CD-4300-A9DC-39AE5FEBF03AQ27008467-A6FF2F3A-55DD-4DBA-A562-2263034D8A15Q27024762-F7D35089-4A7F-4E5A-BC9C-C9DEDF756E95Q27311266-95EE1460-504D-4D9C-AE89-238E80337476Q28387116-8562F757-C1CE-460E-9131-C5E8633C6EADQ28388674-B59D6061-30B3-4C0D-BBF7-F3B81B4570C5Q28743874-A25B3CC2-15B8-4074-BF29-2B80AAADB95CQ30544798-E27FD153-F64D-49A3-970C-9DF8E4E29079Q31041660-7A21D15B-B465-4A9D-B4A3-AD37F1A94412Q33603777-DF282C41-C549-4AC1-81AC-8EE9B87E6232Q33646553-9E82AF47-59B1-4485-B977-1AE568AD2D83Q33770852-19A6B00A-1D7D-4BF2-A7AA-CAAD68A9582DQ33804255-0E434886-8145-4695-99BF-CDCA8220CDA7Q33808567-CC156990-3B8F-45C4-8501-986FA9C604B7Q33998724-14694D43-A6A8-4EE2-9CAC-C768E4D631EAQ34019732-8DE69B08-1CFE-4FBA-97CC-55D6FEC935F4Q34032608-1ED9ED31-58AC-48C0-8153-0DA7E2BA3C86Q34054934-13609AB4-C9EE-43F0-AC0D-FAFEFDC99661Q34061506-F372520A-6A09-4B7E-BDB7-806C46E344A3Q34157725-33E3E47E-9F0E-4460-97FB-40362781654FQ34179611-A5C2CA75-5C82-4ECE-ADC4-CC33A2D3F1EAQ34250995-ECA19A8B-30DC-4511-882D-4F7487343D63Q34273978-29F3FC60-06B2-4F1E-B84D-82F6ED155C35Q34281003-5634A980-1AC9-4E75-A1F0-AFF790A68D97Q34363409-2DA64A14-E0D3-4D31-AD4E-3074A01B9EA8Q34460675-E534E826-1B92-455D-80AF-D81C7E838D0FQ34576895-F5DF9A7A-04F6-4AD8-910C-660E7ECBA454Q34625918-A5B2C694-973B-44AC-9B0C-9999FC3DAD51Q34629589-59335287-F2F3-44BE-8B0B-FE4E58C27902Q34658560-FDF1F3CF-1AA6-456A-8CEC-150FF1F12DB0Q34805469-E0E4752B-EB88-47D5-B8A4-2E0FB931FBF2Q34898429-F7DEA52E-0CFF-49DB-AB03-457D730A7FA0Q35008049-D9D93BBF-454A-4F28-B23F-46A9DF8D36D5Q35071745-C98DF841-AD19-4E98-8664-70C90FCC9495Q35148529-55306D47-6F08-45BC-90BC-F51C2EFB1298Q35162492-7FE05787-A44F-413A-8AA6-E84D83D3D773Q35163858-9D6E7E2D-4781-46A9-B701-75F43B4CAAB1Q35638492-E38E6161-4818-43D1-B368-F0FC3EBCE885
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Plasma urate and risk of Parkinson's disease.
@ast
Plasma urate and risk of Parkinson's disease.
@en
type
label
Plasma urate and risk of Parkinson's disease.
@ast
Plasma urate and risk of Parkinson's disease.
@en
prefLabel
Plasma urate and risk of Parkinson's disease.
@ast
Plasma urate and risk of Parkinson's disease.
@en
P2093
P2860
P921
P356
P1476
Plasma urate and risk of Parkinson's disease.
@en
P2093
A Ascherio
E O'Reilly
M A Schwarzschild
M G Weisskopf
P2860
P2880
P304
P356
10.1093/AJE/KWM127
P407
P50
P577
2007-06-20T00:00:00Z